CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment
CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment
About this item
Full title
Author / Creator
Li, Jun , Huang, Tao , Hua, Jun , Wang, Qiong , Su, Yang , Chen, Ping , Bidlingmaier, Scott , Li, Allan , Xie, Zhongqiu , Bidkar, Anil P. , Shen, Sui , Shi, Weibin , Seo, Youngho , Flavell, Robert R. , Gioeli, Daniel , Dreicer, Robert , Li, Hui , Liu, Bin , He, Jiang and USDOE Office of Science (SC), Office of Isotope R&D and Production (IRP)
Publisher
London: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
We recently identified CD46 as a novel prostate cancer cell surface antigen that shows lineage independent expression in both adenocarcinoma and small cell neuroendocrine subtypes of metastatic castration resistant prostate cancer (mCRPC), discovered an internalizing human monoclonal antibody YS5 that binds to a tumor selective CD46 epitope, and de...
Alternative Titles
Full title
CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment
Authors, Artists and Contributors
Author / Creator
Huang, Tao
Hua, Jun
Wang, Qiong
Su, Yang
Chen, Ping
Bidlingmaier, Scott
Li, Allan
Xie, Zhongqiu
Bidkar, Anil P.
Shen, Sui
Shi, Weibin
Seo, Youngho
Flavell, Robert R.
Gioeli, Daniel
Dreicer, Robert
Li, Hui
Liu, Bin
He, Jiang
USDOE Office of Science (SC), Office of Isotope R&D and Production (IRP)
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_dda216b0fc2a4b11a9340849cfc3ea50
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_dda216b0fc2a4b11a9340849cfc3ea50
Other Identifiers
ISSN
1756-9966,0392-9078
E-ISSN
1756-9966
DOI
10.1186/s13046-023-02636-x
